Didier J Leturcq

This inventor holds 14 USPTO granted patents, plus 3 CIPO patents and 2 EPO patents. Top assignees: Scripps Research Institute, Janssen Pharmaceutica Nv, Janssen Pharmaceuticals, Inc.. Active years: 1998-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Didier J Leturcq. Retrieved from https://idiyas.com/inventor/didier-j-leturcq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14

% Patents Active = 57.1

CIPO Patents = 3

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 77(Granted Patents)

Company Filing History:

8 out of 1,206

Scripps Research Institute

patents

2 out of 2,100

Janssen Pharmaceutica Nv

patents

2 out of 161

Janssen Pharmaceuticals, Inc.

patents

4. 2 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

Years Active: 1998-2015

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9222071 - Cell therapy method for the treatment of tumors (2015-12-29),

2. 9222070 - Cell therapy method for the treatment of tumors (2015-12-29),

3. 8357533 - Preparation of inactivated artificial antigen presenting cells and their use in cell therapies (2013-01-22),

4. 8124408 - Preparation of inactivated artificial antigen presenting cells and their use in cell therapies (2012-02-28),

5. 7326569 - Hybrid cells producing monoclonal anti-CD14 antibodies (2008-02-05),

6. 7247474 - [object Object] (2007-07-24),

7. 6884417 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use (2005-04-26),

8. 6828150 - Antigen presenting system and methods for activation of T-cells (2004-12-07),

9. 6790662 - Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides (2004-09-14),

10. 6461867 - Synthetic antigen presenting matrix (2002-10-08),

11. 6444206 - Methods and compositions for inhibiting CD14 mediated cell activation (2002-09-03),

12. 6232080 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use (2001-05-15),

13. 5820858 - Methods and compositions for inhibiting CD14 mediated cell activation (1998-10-13),

14. 5753504 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding (1998-05-19),

Title: The Innovative Journey of Didier J Leturcq

Introduction: Didier J Leturcq is a visionary inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Didier J Leturcq holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Didier J Leturcq has worked with leading research institutions and tech companies, consistently pushing the boundaries of what is possible in the world of inventions. His passion for innovation has led to the development of cutting-edge solutions that have the potential to revolutionize industries.

Collaborations: Throughout his career, Didier J Leturcq has collaborated with top scientists, engineers, and entrepreneurs, fostering a culture of innovation and excellence. His ability to work across disciplines has resulted in the creation of unique and impactful inventions.

Conclusion: Didier J Leturcq's relentless pursuit of innovation and his commitment to pushing the boundaries of technology make him a true pioneer in the world of inventions. His work continues to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.